Source:http://linkedlifedata.com/resource/pubmed/id/16547486
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2006-4-19
|
| pubmed:abstractText |
To determine the role of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in extranodal NK/T-cell lymphoma patients, we conducted a retrospective analysis. In our previous study, we searched for patients who had received HDC/ASCT and identified 16 eligible patients and compared the treatment outcome with historical control group (n=246). Nine patients received HDC/ASCT in the first (CR1) or second complete remission (CR2), while seven patients received HDC/ASCT as salvage. Twelve of 16 patients achieved or maintained CR after HDC/ASCT. Among the 12 patients, five patients relapsed. Estimated 2-year overall survival (OS) and relapse-free survival (RFS) rates were 71.3+/-12.4% and 25.8+/-14.3%, respectively. There was a tendency of better survival in patients who received HDC/ASCT as compared to those who did not (P=0.091). In subset analysis, patients who underwent HDC/ASCT at CR (P=0.049) and patients with stage III or IV (P=0.001) had a favorable outcome. Patients with NKIPI 3,4 or EUNKTL, who underwent HDC/ASCT had more prolonged survival without statistical significance (P=0.055 and 0.056). In conclusion, HDC/ASCT may be considered as a treatment option for patients with extranodal NK/T-cell lymphoma, especially those in CR, with advanced disease (stage III/IV or EUNKTL) and high NKIPI scores.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BangS MSM,
pubmed-author:EBYT MTM,
pubmed-author:JungC WCW,
pubmed-author:KimKK,
pubmed-author:KwonH CHC,
pubmed-author:KwonJ MJM,
pubmed-author:LUS ISI,
pubmed-author:LeeH RHR,
pubmed-author:LeeJ HJH,
pubmed-author:LeeJJ,
pubmed-author:ParkKK,
pubmed-author:ParkY HYH,
pubmed-author:RyooB YBY,
pubmed-author:SueFF,
pubmed-author:UROM JMJ
|
| pubmed:copyrightInfo |
Bone Marrow Transplantation (2006) 37, 819-824. doi:10.1038/sj.bmt.1705349; published online 20 March 2006.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
819-24
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16547486-Adolescent,
pubmed-meshheading:16547486-Adult,
pubmed-meshheading:16547486-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16547486-Combined Modality Therapy,
pubmed-meshheading:16547486-Female,
pubmed-meshheading:16547486-Humans,
pubmed-meshheading:16547486-Lymphoma, T-Cell,
pubmed-meshheading:16547486-Male,
pubmed-meshheading:16547486-Middle Aged,
pubmed-meshheading:16547486-Retrospective Studies,
pubmed-meshheading:16547486-Stem Cell Transplantation,
pubmed-meshheading:16547486-Survival Analysis,
pubmed-meshheading:16547486-Survivors,
pubmed-meshheading:16547486-Time Factors,
pubmed-meshheading:16547486-Transplantation, Autologous,
pubmed-meshheading:16547486-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.
|
| pubmed:affiliation |
Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|